http://www.lse.co.uk/ OXB Financial Share News Feed - London South East en-us Thu, 23 May 2013 02:39:46 GMT 2007 London South East http://www.lse.co.uk/rss/ 15 LONDON, Nov 29 (Reuters) - Oxford BioMedica PLC: * Imaginab acquires exclusive worldwide licence for 5t4-based imaging http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=2rec6mx2vajg161 Thu, 29 Nov 2012 07:42:53 GMT LONDON, Oct 10 (Reuters) - Britain's Oxford BioMedica said on Wednesday it was closing a mid-stage clinical trial of its cancer vaccine TroVax in U.S. patients with prostate cancer, dealing a further blow to the troubled product. http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=mvoipp8e7c06flb Wed, 10 Oct 2012 07:51:13 GMT LONDON, Oct 10 (Reuters) - Oxford BioMedica PLC: * To close phase II study in US to assess Trovax in patients with prostate http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=91fpd8om25c2qj7 Wed, 10 Oct 2012 06:21:46 GMT LONDON, June 29 (Reuters) - Oxford BioMedica PLC: * Proposed firm placing of £11 million and open offer of up to £5 million http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=9uujmhpbskic143 Fri, 29 Jun 2012 06:39:37 GMT LONDON, June 8 (Reuters) - Oxford BioMedica PLC: * Approval from the UK mhra for manufacturing facility in cowley, Oxford http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=c8svexyuuzryqwo Fri, 08 Jun 2012 06:28:15 GMT LONDON, May 8 (Reuters) - Oxford BioMedica PLC: * Presentation of ocular clinical data at arvo http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=2rwe50uqh4mn3ww Tue, 08 May 2012 06:29:22 GMT LONDON, April 16 (Reuters) - Oxford BioMedica PLC: * Successful completion of prosavin phase i/ii study in parkinson's disease http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=b9nhxqibdnlmbs7 Mon, 16 Apr 2012 06:26:23 GMT March 12 (Reuters) - Oxford BioMedica PLC: * Peel Hunt raises Oxford Biomedica to hold from sell For a summary of rating actions and price target changes on European companies: http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=s1ohk188zcghp3v Mon, 12 Mar 2012 08:54:13 GMT LONDON, March 12 (Reuters) - Oxford BioMedica PLC: * Cubana's interest in the ordinary shares of the company were transferred to http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=f0v8rl4ndtosdia Mon, 12 Mar 2012 07:19:23 GMT LONDON, Feb 10 (Reuters) - Oxford BioMedica PLC: * Appointment of new chief financial officer http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=sj97uth1ybvgi6v Fri, 10 Feb 2012 07:21:05 GMT Dec 15 (Reuters) - Oxford BioMedica PLC: * Peel hunt cuts Oxford Biomedica target price by 50 percent to 3P http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=onus3gohx2njani Thu, 15 Dec 2011 10:02:43 GMT LONDON, Dec 15 (Reuters) - Oxford BioMedica said patients taking a higher dose of its ProSavin drug to treat Parkinson's disease did not show a greater improvement than those taking a lower dose. http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=0n2zjge2qd1q9gh Thu, 15 Dec 2011 09:20:54 GMT LONDON, Dec 15 (Reuters) - Oxford BioMedica PLC: * Interim update on Prosavin Phase I/II study in Parkinson's disease http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=n7egg74hda4exih Thu, 15 Dec 2011 07:20:15 GMT LONDON, Oct 31 (Reuters) - Oxford BioMedica PLC: * Research and development collaboration with mayo clinic, Rochester http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=6k3m69bhz30mj3t Mon, 31 Oct 2011 07:22:46 GMT LONDON, Oct 18 (Reuters) - Oxford BioMedica PLC: * Announces US ind approval for novel ocular product in usher syndrome type 1b http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=8tok894ymnn57pt Tue, 18 Oct 2011 06:30:49 GMT LONDON, Oct 18 (Reuters) - Oxford BioMedica PLC: * Oxford Biomedica announces US IND approval for novel ocular product in usher http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=60krh5mdqmrr47m Tue, 18 Oct 2011 06:18:55 GMT LONDON, June 7 (Reuters) - Oxford Biomedica PLC: * Announces 5t4 antibody research collaboration with imaginab http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=b6hyba2ddne67kd Tue, 07 Jun 2011 06:26:01 GMT LONDON, May 23 (Reuters) - Oxford Biomedica PLC: * New clinical data from prosavin phase i/ii study in parkinson's disease http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=rpnd0n9f57fbsew Mon, 23 May 2011 06:22:30 GMT LONDON, March 21 (Reuters) - Oxford Biomedica PLC: * US IND approval for novel ocular product in Stargardt disease http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=xqpa8zcw9pwtoe1 Mon, 21 Mar 2011 07:24:08 GMT LONDON, March 21 (Reuters) - Oxford Biomedica PLC: * Chairman Alan Kingsman, will leave on 5 may 2011 http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=ltmmkz8wsz3mcj2 Mon, 21 Mar 2011 07:20:47 GMT March 3 (Reuters) - Oxford Biomedica PLC: * Panmure cuts Oxford Biomedica PLC price target to 9P from 17P; rating http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=1mnfpqy9vzb8wcm Thu, 03 Mar 2011 10:03:19 GMT LONDON, Jan 31 (Reuters) - Oxford Biomedica PLC: * Acquisition of manufacturing facility http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=nmiufq2m9ezd64k Mon, 31 Jan 2011 07:38:47 GMT LONDON, Dec 22 (Reuters) - Oxford Biomedica PLC: * Update on prosavin phase i/ii study in parkinson's disease http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=815bx3usm5jix8e Wed, 22 Dec 2010 07:09:37 GMT LONDON, Dec 13 (Reuters) - Oxford Biomedica PLC: * Proposed firm placing and placing and open offer of up to £20 million http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=bjhj3am0ufqk8wx Mon, 13 Dec 2010 08:05:54 GMT LONDON, Nov 9 (Reuters) - Oxford Biomedica PLC: * US FDA approved ind application for phase i/ii clinical development of http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=qqm75zwzfqjj4pf Tue, 09 Nov 2010 07:31:04 GMT LONDON, Oct 14 (Reuters) - Oxford Biomedica PLC: * Publication of trovax  phase III results in metastatic renal cancer in http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=oppd3q3sp6rkk5d Thu, 14 Oct 2010 12:11:36 GMT LONDON, Aug 18 (Reuters) - Oxford BioMedica PLC: * Announces licensing agreement with Emergent Biosolutions Inc http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=dawchn2rtdbdobv Wed, 18 Aug 2010 06:22:39 GMT LONDON, July 26 (Reuters) - Oxford BioMedica PLC: * Announces FDA approval for TroVax phase II study in prostate cancer http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=n7kudliig9at8wa Mon, 26 Jul 2010 06:26:42 GMT LONDON, June 24 (Reuters) - Oxford BioMedica PLC: * Announces collaborative phase I/II study to evaluate Trovax in mesothelioma, with a team of cancer immunologists led by Dr Zsuzsanna Tabi at Cardiff University http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=388qibo7mh5492x Thu, 24 Jun 2010 06:22:37 GMT LONDON, June 18 (Reuters) - Oxford Biomedica PLC: * Announces amendment to 5t4 licence agreement with cancer research technology http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=qv3q8n1a0hgzj33 Fri, 18 Jun 2010 06:24:03 GMT LONDON, June 14 (Reuters) - Oxford Biomedica PLC: * Two-year phase I/II results of ProSavin in Parkinson's shows sustained http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=czg0dgfy18dsrom Mon, 14 Jun 2010 06:26:50 GMT LONDON, May 19 (Reuters) - Oxford Biomedica PLC: * At 31 March 2010 the company had a net cash1 balance of £21.3 million http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=6j5crl0lez8f00k Wed, 19 May 2010 06:32:16 GMT LONDON, March 10 (Reuters) - Oxford BioMedica PLC: * Year net loss before exceptional items of £9.5 million (2008: £5.5 million) http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=ic1resohwaxdzy3 Wed, 10 Mar 2010 07:27:07 GMT LONDON, Jan 27 (Reuters) - Oxford Biomedica PLC: * Oxford Biomedica Plc and ALS Therapy Development Institute extend collaboration to develop gene therapies for amyotrophic lateral sclerosis http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=bcmqc7e1ts5j88w Wed, 27 Jan 2010 13:18:43 GMT LONDON, Oct 15 (Reuters) - British gene therapy specialist Oxford BioMedica said on Thursday patients had responded well to the second dose of its experimental Parkinson's disease drug, ProSavin, news that sent its shares sharply higher. http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=zfq31frn5ncxclm Thu, 15 Oct 2009 09:31:18 GMT STOCKS NEWS Reuters Results diary Europe Real-time Equity News http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=azpv93c4flv2n8m Thu, 15 Oct 2009 08:13:53 GMT LONDON, Oct 15 (Reuters) - Oxford BioMedica PLC: * All patients treated at the second dose level with Parkinson's disease gene therapy drug ProSavin have completed their six-month assessments and have shown further improvement in motor function (UPDRS III 'OFF' score) http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=iztzq94mvndufk5 Thu, 15 Oct 2009 06:23:37 GMT LONDON, Oct 14 (Reuters) - Long-term tests on monkeys using Oxford BioMedica's gene therapy ProSavin suggest it can treat Parkinson's disease without causing the jerky, involuntary movements associated with current drugs, researchers said on Wednesday. http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=kq8wif1mbqsa4dh Wed, 14 Oct 2009 18:15:07 GMT BERLIN, Sept 22 (Reuters) - A therapeutic cancer vaccine from Oxford BioMedica that failed in a clinical study may still help a subset of patients, researchers said on Tuesday. http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=dw62masm2o45nf0 Tue, 22 Sep 2009 08:49:28 GMT STOCKS NEWS Reuters Results diary Europe Real-time Equity News http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=5plv1y3ckuc5ycp Tue, 22 Sep 2009 08:14:24 GMT BERLIN, Sept 22 (Reuters) - A therapeutic cancer vaccine from Oxford BioMedica that failed in a clinical study may still help a subset of patients, researchers said on Tuesday. http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=9f7amx31xxs1vpo Tue, 22 Sep 2009 06:15:06 GMT LONDON, Aug 27 (Reuters) - Oxford BioMedica PLC: * H1 net loss of £0.5 million (H1 2008: £1.1 million) http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=mvdvkhgz840pfxl Thu, 27 Aug 2009 06:32:03 GMT LONDON, July 13 (Reuters) - Oxford Biomedica PLC: * Oxford Biomedica announces update on phase I/II study of ProSavin in http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=vul0o7uh4bx8xde Mon, 13 Jul 2009 06:26:59 GMT STOCKS NEWS Reuters Results diary Europe Real-time Equity News http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=laujdaepve7ku65 Mon, 06 Jul 2009 14:03:07 GMT STOCKS NEWS Reuters Results diary Europe Real-time Equity News http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=kmxpexwerbknh7a Mon, 06 Jul 2009 10:10:53 GMT LONDON, July 6 (Reuters) - British gene therapy specialist Oxford BioMedica said on Monday that a ruling by U.S. regulators has cleared the way for it to develop its lead drug in a range of cancers, following a review of a failed trial. http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=f3ssqq8b86c06t8 Mon, 06 Jul 2009 07:58:12 GMT LONDON, July 6 (Reuters) - Oxford Biomedica PLC: * FDA supported proposal to pursue further development of TroVax in metastatic cancer indications http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=71w43qwen5sfkan Mon, 06 Jul 2009 06:46:04 GMT STOCKS NEWS Reuters Results diary Europe Real-time Equity News http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=6ibb1ztr6sc9g4n Mon, 01 Jun 2009 11:50:24 GMT LONDON, June 1 (Reuters) - Oxford Biomedica PLC: * In all trials, Trovax was well tolerated with no serious adverse events http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=kp2f5tz85y8ya60 Mon, 01 Jun 2009 06:48:35 GMT STOCKS NEWS Reuters Results diary Europe Real-time Equity News http://www.lse.co.uk/ShareNews.asp?shareprice=OXB&ArticleCode=sk3mouzlvs96gke Thu, 14 May 2009 11:18:26 GMT